Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector” and produced by NetworkNewsWire (“NNW”).
To hear the NetworkNewsAudio version, visit: http://nnw.fm/7MW1l
To read the full editorial, visit: http://nnw.fm/xk1bN
With significant milestones being met, Genprex Inc. (NASDAQ:GNPX) is pressing forward with its strategy objectives to reprogram the course of cancer. The company plans on continuing to conduct ongoing and new clinical trials as well as pursue strategic partnerships with organizations whose missions align with its own. One of these existing partnerships — with manufacturing partner Aldevron — recently resulted in the successful completion of the manufacturing of the TUSC2 plasmid DNA.
Genprex is also preparing to commercialize Oncoprex. Most recently, the company announced that it has initiated the first phase of branding the immunogene therapy and has completed the creation and submission of nonproprietary drug name selections to the American Medical Associations’ United States Adopted Names Council.
In addition, Genprex is planning to investigate the effectiveness of Oncoprex in other cancers as well as further develop platform technology.
About Genprex Inc.
Genprex Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell-signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc and LinkedIn at linkedin.com/company/genprex.
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Upcoming Life Sciences Events
- September 2019
- Dusseldorf: 5th Annual Pre-Filled Syringes & Injectables Summit
- Munich: The Biotech & Pharma Summit: Drug Delivery & Formulation
- Brussels: The Pharma Forecasting Course